Results 111 to 120 of about 4,166,301 (304)

Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey

open access: yesArthritis Care &Research, EarlyView.
Objective Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc ...
Sabrina Hoa   +3 more
wiley   +1 more source

Effect of adverse drug reactions on length of stay in surgical intensive care units

open access: yes, 2003
Objective., To determine the frequency of adverse drug reactions in surgical intensive care units and evaluate their effect on the length of stay. Design: Prospective cohort study.
Pérez Aguirre, María Elia   +6 more
core   +1 more source

Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization

open access: yes, 2006
PURPOSE: To use computerized medical records to study the frequency of adverse drug reactions (ADR) as a cause for acute admission to a university hospital.METHODS: Computerized medical records in 168 consecutively acutely admitted cases to a short-term ...
Ulf Bergman   +11 more
core   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

open access: yesArthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato   +27 more
wiley   +1 more source

Extensively drug resistant tuberculosis in South Africa [PDF]

open access: yes, 2011
Includes abstract.Includes bibliographical references (leaves 161-168).There are few data for treatment-related outcomes in patients with XDR tuberculosis in settings with high HIV prevalence.
Shean, Karen Penelope
core   +1 more source

Adverse drug reactions

open access: yes, 2010
Адрес за кореспонденция: Д-р Румен Николов, дм, Катедра по фармакология и токсикология, Медицински факултет, Медицински университет, ул. ”Здраве” № 2, 1431 София, тел.
Николов/Nikolov, Р. П./ R. P.
core   +1 more source

Editorial: Pharmacogenomics of Adverse Drug Reactions

open access: yesFrontiers in Genetics, 2022
Moneeza K. Siddiqui   +3 more
doaj   +1 more source

A Causality Driven Approach to Adverse Drug Reactions Detection in Tweets

open access: yes, 2019
Social media sites such as Twitter is a platform where users usually express their feelings, opinions, and experiences, e.g., users often share their experiences about medications including adverse drug reactions in their tweets.
Wang, J   +5 more
core   +1 more source

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho   +4 more
wiley   +1 more source

Caregiver Perspectives on the Burden of Disease and Treatment in Uncontrolled Gout

open access: yesArthritis Care &Research, EarlyView.
Objective Uncontrolled gout (UG) refers to persistently elevated serum urate (SU) levels >6 mg/dL and ongoing gout symptoms despite use of urate‐lowering therapy (ULT). The objective of this study was to evaluate the burden associated with informal caregiving for individuals with UG.
Angelo Gaffo   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy